Clinical Trial Update: Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 study of magrolimab in combination with cytotoxic chemotherapy for advanced urothelial carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Magrolimab (magrolimab)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Advanced Urothelial Carcinoma | Phase 1 | Status: WITHDRAWN